innoscripta SE: Successful First Half of 2026

innoscripta reported H1 2026 revenue up 43% YoY to EUR 63.1M and adjusted EBIT up 49% YoY to EUR 36.4M, implying a 57.7% adjusted EBIT margin (vs 56.9% unadjusted). The company credited continued growth in part to Germany’s R&D tax allowance (Forschungszulage), driving customer count to 2,900+. It also reaffirmed 2026 guidance of at least EUR 140M revenue and at least EUR 80M EBIT as it expands internationally (France/UK/US first contracts secured).

Analysis

The market should treat this as a quality-of-growth check, not a simple beat. The real signal is that the business is converting a policy-driven workflow into repeatable software economics: if the approval cycle remains stable, the company can keep layering volume without a matching increase in overhead, which is why margins can stay unusually high even while headcount expands internationally. That also means the equity is more exposed to operational timing than to classic SaaS churn risk.

The key second-order issue is that the current growth rate likely embeds a benign regulatory and processing environment; any slowdown in application submissions or approvals would hit revenue before the market sees it in customer counts. In the next 1-3 months, the earnings call matters more than the release: investors will key on forward booking quality, cash conversion, and whether new geographies require localized labor that drags near-term EBIT. If management sounds dependent on governmental throughput rather than product-led adoption, the multiple can de-rate quickly despite headline growth.

Contrarian view: the consensus may be over-crediting international expansion as a pure software story. This looks like a hybrid of SaaS and regulated workflow outsourcing, which usually deserves a lower terminal multiple until cross-border replication is proven across at least one budget cycle. Falsifier: if H2 revenue run-rate and margin both hold while France/UK/US contracts begin recurring, then the higher-margin platform narrative becomes credible and the stock deserves a structural rerating.

Key Decisions for Investors

• Buy on post-call weakness only if management reiterates 2026 guidance and frames H2 growth as approval-timing neutral; use a 1-3 month horizon, with downside governed by any commentary that approvals are slipping.
• Avoid chasing the first move higher; wait for the call transcript and look for confirmation that international hires are not compressing the >57% EBIT margin. If margins step down by >300 bps sequentially, the multiple case weakens.
• If you have access to the name, run a pair: long innoscripta vs short a broad software proxy like WCLD/IGV on a 3-6 month horizon. The edge is that this name has more policy-linked operating leverage than the typical cloud basket, so it can outperform if the regulatory workflow remains stable.
• Set a watch item on German R&D tax allowance policy and approval-cycle data over the next 1-2 quarters. A change in subsidy economics or slower approvals is the cleanest thesis breaker.
• For a lower-risk expression, consider a call spread rather than outright equity if implied volatility is elevated into the earnings call; the upside is a rerating on international traction, while the main risk is that the market deems the growth repeatability unproven.